Bortezomib in multiple myeloma and lymphoma.

GUIDELINE TITLE
Bortezomib in multiple myeloma and lymphoma.

BIBLIOGRAPHIC SOURCE(S)
Reece D, Kouroukis T, Haynes AE, Imrie K. Bortezomib in multiple myeloma and lymphoma. Toronto (ON): Cancer Care Ontario (CCO); 2008 Nov 24. 41 p. (CED-CCO special advice report; no. 11). [33 references]

GUIDELINE STATUS
This is the current release of the guideline.

The CED-CCO Special Advice report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site for details on any new evidence that has emerged and implications to the guidelines.

abrir aquí para acceder al documento NGC AHRQ completo:
Bortezomib in multiple myeloma and lymphoma.